Skip to main content

Acute Lung Injury clinical trials at UC Irvine

2 in progress, 1 open to eligible people

Showing trials for
  • Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

    open to eligible people ages 18-65

    To evaluate the safety and efficacy of intravenous administration of bone marrow derived extracellular vesicles, ExoFlo, versus placebo as treatment for hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).

    Orange, California and other locations

  • Add-on Reparixin in Adult Patients With ARDS

    Sorry, not currently recruiting here

    Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.

    Orange, California and other locations

Last updated: